Interestingly, post hoc analyses from both the CREDENCE and DAPA-HF trialssuggest that SGLT2 inhibitor use may reduce the risk of significanthyperkalemia, an observation that could facilitate treatment withfinerenone.53,90 Potassium-binding agents may also help ensurepatients can benefit from finerenone treatment. This evidence concerns the gene SLC5A2 and hydrops fetalis.